FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2007261008> ?p ?o ?g. }

• W2007261008 endingPage "368" @default.
• W2007261008 startingPage "361" @default.
• W2007261008 abstract "The aim of this study was to evaluate the impact of platinum dose intensity on pathological response rate and overall survival in patients with advanced ovarian adenocarcinoma.Between February 1992 and December 1996, 195 previously untreated patients with FIGO stage IIb-c, IIIb-c, or IV with macroscopic residual disease after suboptimal debulking surgery were randomized to receive CCC (100 mg/m(2) of cisplatin, 300 mg/m(2) of cyclophosphamide, 300 mg/m(2) of carboplatin, n = 96) or CC (100 mg/m(2) of cisplatin, 600 mg/m(2) of cyclophosphamide, n = 99) for six courses at 28-day intervals. A second-look laparotomy was planned at the end of chemotherapy.In the CCC arm, the platinum compound received dose intensity and relative total dose were 85 and 76%; in the CC arm, they were 94 and 85%. Grade 3-4 toxicity was more frequent in the CCC arm than in the CC arm for leukopenia (56% vs 26%, P < 0.001), febrile neutropenia (18% vs 4%, P = 0.002), anemia (31% vs 5%, P < 0.001), thrombopenia (55% vs 4%, P < 0.001), and ototoxicity (8% vs 0%, P < 0.001). The pathologic complete response rate was 22 and 14% in the CCC and CC arms, respectively (P = 0.19). With a median follow-up of 53 months, the median time to failure and the 3-year treatment failure-free survival rate were 17.4 months and 22% vs 13 months and 11% in the two arms, respectively (P = 0.01). The median survival time and the 3-year overall survival rate were, respectively, 30 months and 42% vs 25 months and 33% (P < 0.20).The platinum dose intensification (1.6-fold increase) obtained with the CCC association improves the treatment failure-free survival without significant impact on overall survival when compared with the CC regimen in suboptimal debulked ovarian adenocarcinoma. However, because of its high rate of hematologic toxicity and ototoxicity, this association cannot be recommended for routine practice." @default.
• W2007261008 created "2016-06-24" @default.
• W2007261008 creator A5002640605 @default.
• W2007261008 creator A5007583147 @default.
• W2007261008 creator A5012023155 @default.
• W2007261008 creator A5018864858 @default.
• W2007261008 creator A5021344518 @default.
• W2007261008 creator A5033496112 @default.
• W2007261008 creator A5041283530 @default.
• W2007261008 creator A5057701424 @default.
• W2007261008 creator A5070598939 @default.
• W2007261008 creator A5076276973 @default.
• W2007261008 creator A5079169911 @default.
• W2007261008 creator A5080896131 @default.
• W2007261008 creator A5084467861 @default.
• W2007261008 date "2000-09-01" @default.
• W2007261008 modified "2023-09-27" @default.
• W2007261008 title "High-Dose Platinum versus Standard Dose in Advanced Ovarian Carcinoma: A Randomized Trial from the Gynecologic Cooperative Group of the French Comprehensive Cancer Centers (FNCLCC)" @default.
• W2007261008 cites W1758230404 @default.
• W2007261008 cites W1770712556 @default.
• W2007261008 cites W1851054576 @default.
• W2007261008 cites W1873801781 @default.
• W2007261008 cites W1971839081 @default.
• W2007261008 cites W1972486840 @default.
• W2007261008 cites W1978009985 @default.
• W2007261008 cites W1984351265 @default.
• W2007261008 cites W1995975732 @default.
• W2007261008 cites W1996131136 @default.
• W2007261008 cites W2000747010 @default.
• W2007261008 cites W2013528590 @default.
• W2007261008 cites W2021115479 @default.
• W2007261008 cites W2076446092 @default.
• W2007261008 cites W2088865525 @default.
• W2007261008 cites W2113067724 @default.
• W2007261008 cites W2113394852 @default.
• W2007261008 cites W2117995467 @default.
• W2007261008 cites W2122049931 @default.
• W2007261008 cites W2122731269 @default.
• W2007261008 cites W2129678716 @default.
• W2007261008 cites W2168284025 @default.
• W2007261008 cites W2170134215 @default.
• W2007261008 cites W2258453408 @default.
• W2007261008 cites W2261061437 @default.
• W2007261008 cites W2284073724 @default.
• W2007261008 cites W2328421677 @default.
• W2007261008 cites W2414266556 @default.
• W2007261008 cites W4254521436 @default.
• W2007261008 doi "https://doi.org/10.1006/gyno.2000.5923" @default.
• W2007261008 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/10985895" @default.
• W2007261008 hasPublicationYear "2000" @default.
• W2007261008 type Work @default.
• W2007261008 sameAs 2007261008 @default.
• W2007261008 citedByCount "22" @default.
• W2007261008 countsByYear W20072610082015 @default.
• W2007261008 countsByYear W20072610082017 @default.
• W2007261008 crossrefType "journal-article" @default.
• W2007261008 hasAuthorship W2007261008A5002640605 @default.
• W2007261008 hasAuthorship W2007261008A5007583147 @default.
• W2007261008 hasAuthorship W2007261008A5012023155 @default.
• W2007261008 hasAuthorship W2007261008A5018864858 @default.
• W2007261008 hasAuthorship W2007261008A5021344518 @default.
• W2007261008 hasAuthorship W2007261008A5033496112 @default.
• W2007261008 hasAuthorship W2007261008A5041283530 @default.
• W2007261008 hasAuthorship W2007261008A5057701424 @default.
• W2007261008 hasAuthorship W2007261008A5070598939 @default.
• W2007261008 hasAuthorship W2007261008A5076276973 @default.
• W2007261008 hasAuthorship W2007261008A5079169911 @default.
• W2007261008 hasAuthorship W2007261008A5080896131 @default.
• W2007261008 hasAuthorship W2007261008A5084467861 @default.
• W2007261008 hasConcept C121608353 @default.
• W2007261008 hasConcept C126322002 @default.
• W2007261008 hasConcept C126894567 @default.
• W2007261008 hasConcept C141071460 @default.
• W2007261008 hasConcept C2776283816 @default.
• W2007261008 hasConcept C2776694085 @default.
• W2007261008 hasConcept C2776755627 @default.
• W2007261008 hasConcept C2778239845 @default.
• W2007261008 hasConcept C2780427987 @default.
• W2007261008 hasConcept C2780873365 @default.
• W2007261008 hasConcept C2781100745 @default.
• W2007261008 hasConcept C2781451048 @default.
• W2007261008 hasConcept C71924100 @default.
• W2007261008 hasConcept C90924648 @default.
• W2007261008 hasConceptScore W2007261008C121608353 @default.
• W2007261008 hasConceptScore W2007261008C126322002 @default.
• W2007261008 hasConceptScore W2007261008C126894567 @default.
• W2007261008 hasConceptScore W2007261008C141071460 @default.
• W2007261008 hasConceptScore W2007261008C2776283816 @default.
• W2007261008 hasConceptScore W2007261008C2776694085 @default.
• W2007261008 hasConceptScore W2007261008C2776755627 @default.
• W2007261008 hasConceptScore W2007261008C2778239845 @default.
• W2007261008 hasConceptScore W2007261008C2780427987 @default.
• W2007261008 hasConceptScore W2007261008C2780873365 @default.
• W2007261008 hasConceptScore W2007261008C2781100745 @default.
• W2007261008 hasConceptScore W2007261008C2781451048 @default.
• W2007261008 hasConceptScore W2007261008C71924100 @default.
• W2007261008 hasConceptScore W2007261008C90924648 @default.
• W2007261008 hasIssue "3" @default.

• next